Pneumologisches Studienzentrum München-West

The Pneumologisches Studienzentrum München‑West concentrates on cystic fibrosis within the broader field of respiratory tract diseases, aiming to evaluate the safety and tolerability of innovative inhaled treatments.

• Safety and tolerability assessments
• Multiple ascending dose investigations
• Early signals of therapeutic benefit
• Patient‑reported outcome measures

These studies are designed to advance therapies that could improve lung function and quality of life for individuals living with cystic fibrosis.

Research at the Munich‑West site focuses on bronchiectasis, a chronic respiratory tract disease, evaluating new oral agents that may lower the frequency of pulmonary exacerbations.

• Comparative effectiveness versus placebo
• Reduction in annualised exacerbation rates
• Long‑term disease management strategies
• Impact on daily activity and wellbeing

The goal is to provide patients with more effective options that address the underlying inflammation and improve overall respiratory health.